Viewing Study NCT05878028


Ignite Creation Date: 2025-12-26 @ 11:14 AM
Ignite Modification Date: 2025-12-26 @ 11:14 AM
Study NCT ID: NCT05878028
Status: RECRUITING
Last Update Posted: 2024-05-23
First Post: 2023-05-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Sponsor: Quanli Gao
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module